Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Executive Summary

Steroid treatment like Emflaza is considered standard of care and availability of other products may make payer discussions difficult.


Related Content

Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.
Emflaza's 505(b)(2) Pathway Review: Rare, But With Precedent
PTC Gambles On Success With Emflaza; Says Price Revision Is Needed
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Marathon's High-Priced Window May Not Stay Open Long
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
Priority Review Politics: With Two Pending DMD Products, FDA Still Faces Community Anxiety
Priority Review Vouchers Appear To Be Dropping In Price
KV’s Suit Against FDA Is Revived By Thiopental Ruling, Compounding Law


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts